January 2025 in “Frontiers in Medicine” Hair follicles are key to treating vitiligo and alopecia areata, but challenges exist.
36 citations,
May 2011 in “Dermatologic therapy” No treatments fully cure or prevent alopecia areata; some help but have side effects or need more research.
April 2021 in “Research Square (Research Square)” Achieving 80% or more scalp hair regrowth is considered a successful treatment for significant hair loss.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
2 citations,
August 2022 in “JAAD case reports” COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.
Current treatments for alopecia areata often fail to achieve and maintain significant hair regrowth.
3 citations,
September 2021 in “Journal of Investigative Dermatology” Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
130 citations,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
6 citations,
February 2021 in “Advances in Clinical and Experimental Medicine” Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.
4 citations,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
1 citations,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
43 citations,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
2 citations,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
January 2024 in “Medicine” Hypothyroidism is often linked to the hair loss condition telogen effluvium.
September 2023 in “British Journal of Dermatology” Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
1 citations,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
1 citations,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
1 citations,
January 2021 in “Journal of clinical and diagnostic research” Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
17 citations,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
13 citations,
February 2019 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
January 2019 in “Egyptian Journal of Dermatology and Venereology /Egyptian Journal of Dermatology and Venerology” Mixing calcipotriol with a steroid is almost as effective as using a steroid alone for alopecia areata and has fewer side effects.